Is it fair to say the recent focus on the options and piggies...

Is it fair to say the recent focus on the options and piggies does nothing to attract new investors?

I understand they are important as a source of fund to advance the trial programme.

Maybe the science around Bisantrane and RC220 is settled for LT committed shareholders, and the potential markets and revenues are all done and dusted by the Triangle report, so most of the discussions seem to be centred around taking advantage of the options and 'piggies', and maximising the number of shares and the almost assured returns, just multiply the no. Of shares you hold by the Triangle report's projected sp.

For myself, I have freed up some capital but still not ready to buy back in for some reason.

The sp seems to be drifting through lack of news in the next few months at least, and lack of discussions on the drug itself or the cancer treatment landscape.

imho.